Amyloid in Alzheimer’s is a whole-body problem, not just a brain one
Alzheimer’s is considered a brain disease. But the protein that clumps in the brains of those affected, amyloid-beta, circulates throughout the entire body. The liver, kidneys, and gut all play a role in clearing it. The researchers argue that therapies focused only on the brain are missing a large part of the picture.
Amyloid-beta is a protein that forms clumps in the brains of people with Alzheimer’s disease. For years, research focused almost exclusively on clearing those clumps from brain tissue. The benefits of drugs that did so turned out to be modest. One possible explanation: amyloid-beta exists in dynamic equilibrium between the brain and the rest of the body. What accumulates in the brain depends partly on how well the body clears it elsewhere.
Four exit routes from the brain
The authors describe four main routes by which amyloid-beta leaves the brain: across the blood-brain barrier, through cerebrospinal fluid, via venous drainage along the meninges, and through the glymphatic system, a network of fluid channels around blood vessels in the brain that is most active during sleep. All these routes eventually lead to the bloodstream, and from there to the liver, kidneys, and gastrointestinal tract.
The liver appears to be the primary clearance site for amyloid-beta in the blood. But the authors emphasize that no single route is solely responsible for the problem. In Alzheimer’s, the issue is more likely the loss of coordination among all these routes at once.
Combination therapy as a new direction
This has practical implications. If amyloid-beta accumulation is a systemic problem, treatment may also need to target multiple routes simultaneously. The authors discuss approaches including compounds that improve glymphatic flow, support liver clearance, and help maintain blood-brain barrier function. Blood filtration to remove amyloid-beta from circulation is also discussed as a potential strategy.
This is a review article, not a clinical trial. The authors make a case for a new framework, not a proven therapy. But the argument fits a growing view that Alzheimer’s may be a systemic disease requiring a systemic approach.
Search terms to explore further: peripheral amyloid-beta clearance, glymphatic system Alzheimer’s, systemic amyloid homeostasis